.Attributes Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of patients with HER2+ innovative bosom cancer cells and energetic or even stable mind metastases presented consistent intracranial task as well as systemic effectiveness of T-DXd.